Clinical Trial Update: Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating SU 11248 (Sutent) in combination with standard chemotherapy for FLT3-mutated acute myeloid leukemia in patients over 60 ye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• SU 11248 (Sutent) (sunitinib)

Snippet

Sponsor: Universitätsklinikum Hamburg-Eppendorf | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: COMPLETED